Hot Products
| Catalog No. | Information |
| CFN98703 | Atraric acid Atraric acid derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists, that can be used for prophylaxis or treatment of prostatic diseases. It inhibits PTP1B activity in a dose-dependent manner with IC50 values of 51.5 uM, suggest that atraric acid has potential to treat diabetes. |
| CFN98824 | Atropine Atropine is a competitive antagonist of the muscarinic acetylcholine receptors (acetylcholine being the main neurotransmitter used by the parasympathetic nervous system), used to treat certain types of nerve agent and pesticide poisonings, some types of slow heart rate, and to decrease saliva production during surgery. |
| CFN90575 | Atropine sulfate Atropine sulfate causes a significant increase in IOP when given both topically and by intramuscular injection. |
| CFN70157 | Atropine sulfate monohydrate Atropine sulfate monohydrate has anticholinergic activity.Atropine sulfate monohydrate can inhibit dose-dependently spontaneous bladder contractions caused by raising the intravesical volume in conscious rats. |
| CFN98530 | Aucubin Aucubin is an iridoid glycoside with a wide range of biological activities, including pancreas-protective, chondroprotective, antispasmodic, liver-protective, anti-inflammatory, anti-microbial, antioxidant, anti-algesic as well as anti-tumor activities. Aucubin prevents neuronal death in the hippocampal CA1 region in rats with diabetic encephalopathy, it also has protective effects on H2O2-induced apoptosis in PC12 cells. Aucubin may improve obesity-induced atherosclerosis by attenuating TNF-α-induced inflammatory responses. Aucubin suppresses hepatitis B viral DNA replication in vitro. |
| CFN89159 | Aucuparin Aucuparin is a phytoalexin, it shows significant scavenging activity by the ABTS and FRAP assays. Aucuparin exhibits potent inhibitory activity against fMLP-induced superoxide (O(*-)(2)) production by human neutrophils with the IC(50) value of 17.0+/-6.8 microM. |
| CFN98984 | Aurantiamide Aurantiamide acetate has anti-cancer, anti-inflammatory and antinociceptive activities, it may suppress the growth of malignant gliomas by blocking autophagic flux, it also inhibits cysteine proteinases, in particular, cathepsin L (3.4.22.15) and B (3.4.22.1) with IC50 of 12 microM and 49 microM, respectively . Aurantiamide acetate has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB, JNK and p38 pathways. |
| CFN99732 | Aurantio-obtusin Aurantio-obtusin possesses anti-allergic, vasorelaxation, hypotensive and hypolipidemic effects, it is a promising osteoanabolic compound with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases. Aurantio-obtusin can inhibit allergic responses in IgE-mediated mast cells and anaphylactic models, it suppresses degranulation, histamine production, and reactive oxygen species generation and inhibits the production and mRNA expression of tumor necrosis factor-α and interleukin-4, and also suppresses the prostaglandin E2 production and expression of cyclooxygenase 2. |
| CFN93172 | Aurantio-obtusin beta-D-glucoside Reference standards. |
| CFN98787 | Auraptene Auraptene possesses anticarcinogenic, cardioprotective, anti-inflammatory, anti-oxidant, antihelicobacter, antigenotoxic, and neuroprotective effects. Auraptene has a potential to attenuate chronic inflammation in adipose tissue and to improve obesity-related insulin resistance, and has protective effects in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. |
